1 | clinical decision support tool | | | | | | | 4 | 0.66% |
2 | the clinical decision support | | | | | | | 2 | 0.33% |
3 | diagnosis and management of | | | | | | | 2 | 0.33% |
4 | by the european union | | | | | | | 2 | 0.33% |
5 | cofunded by the european | | | | | | | 2 | 0.33% |
6 | clinical decision support tools | | | | | | | 2 | 0.33% |
7 | treatment of stroke and | | | | | | | 1 | 0.17% |
8 | and treatment of stroke | | | | | | | 1 | 0.17% |
9 | management and treatment of | | | | | | | 1 | 0.17% |
10 | studies which will be | | | | | | | 1 | 0.17% |
11 | which will be used | | | | | | | 1 | 0.17% |
12 | will be used to | | | | | | | 1 | 0.17% |
13 | personalised risk prediction optimised | | | | | | | 1 | 0.17% |
14 | for personalised risk prediction | | | | | | | 1 | 0.17% |
15 | existing mechanistic virtual twin | | | | | | | 1 | 0.17% |
16 | stroke and enhanced rehabilitation | | | | | | | 1 | 0.17% |
17 | tools for personalised risk | | | | | | | 1 | 0.17% |
18 | and tools for personalised | | | | | | | 1 | 0.17% |
19 | twins and tools for | | | | | | | 1 | 0.17% |
20 | virtual twins and tools | | | | | | | 1 | 0.17% |
21 | be used to test | | | | | | | 1 | 0.17% |
22 | used to test and | | | | | | | 1 | 0.17% |
23 | integrated multiscale computational models | | | | | | | 1 | 0.17% |
24 | develop integrated multiscale computational | | | | | | | 1 | 0.17% |
25 | will develop integrated multiscale | | | | | | | 1 | 0.17% |
26 | target will develop integrated | | | | | | | 1 | 0.17% |
27 | validate the personalised tools | | | | | | | 1 | 0.17% |
28 | of stroke and enhanced | | | | | | | 1 | 0.17% |
29 | target will also help | | | | | | | 1 | 0.17% |
30 | clinical studies which will | | | | | | | 1 | 0.17% |
31 | heart the brain and | | | | | | | 1 | 0.17% |
32 | twins to deliver more | | | | | | | 1 | 0.17% |
33 | these twins to deliver | | | | | | | 1 | 0.17% |
34 | enriching these twins to | | | | | | | 1 | 0.17% |
35 | collect new observational data | | | | | | | 1 | 0.17% |
36 | new observational data via | | | | | | | 1 | 0.17% |
37 | observational data via 4 | | | | | | | 1 | 0.17% |
38 | and the neuromusculoskeletal system | | | | | | | 1 | 0.17% |
39 | brain and the neuromusculoskeletal | | | | | | | 1 | 0.17% |
40 | the brain and the | | | | | | | 1 | 0.17% |